TB-500 Fragment vs Full-Length Thymosin Beta-4: Sequence Identity on the COA
In research commerce, "TB-500" can mean the Ac-LKKTETQ fragment or full-length synthetic thymosin β4. How to verify sequence identity on a certificate of analysis — HPLC, mass spec, and labeling — without dosing or efficacy claims.
> Research disclaimer: This article covers analytical chemistry and research-commerce labeling for informational purposes only. TB-500 / thymosin β4 materials sold as research chemicals are not FDA-approved drugs. Nothing here is medical advice, a dosing protocol, an efficacy claim, or a recommendation for human or veterinary use.
Why "TB-500" Is Not Always the Same Molecule
In the published actin-biology literature, thymosin beta-4 (Tβ4) usually means a 43-amino-acid actin-sequestering peptide first characterized from thymus extracts and later shown to be abundant in many mammalian cells (classic primary literature includes Safer, Elzinga & Nachmias, 1991, and related actin-binding work). Separately, a large body of structure–function research focuses on a short N-terminally acetylated fragment corresponding roughly to residues 17–23 of Tβ4 — commonly written Ac-LKKTETQ (Ac-LKKTETQ-OH) — which contains an actin-binding motif studied in papers such as Ho et al. (2012) and Esposito et al. (2012).
In research-peptide commerce, the trade name "TB-500" is used for both of those chemistries and, occasionally, for other related synthetic materials. That naming overlap is the entire point of this guide. A Certificate of Analysis (COA) that says "TB-500, 99% HPLC" without a stated sequence and a matching mass does not tell a working researcher which molecule is in the vial. Our third-party testing and purity guide covers what HPLC and MS can and cannot verify after the fact. Our manufacturing and synthesis guide covers how solid-phase synthesis introduces deletion sequences and related impurities. This page sits between those two: identity — fragment versus full-length — before purity percentages are even meaningful.
What Primary Literature Usually Means by Each Name
| Label in commerce | What primary literature usually describes | Approximate mass scale (order of magnitude) |
|---|---|---|
| Full-length thymosin β4 / Tβ4 | 43-residue actin-sequestering peptide | ~4.9 kDa class (literature molecular weight near 4,963 Da for the mature peptide in classic descriptions) |
| TB-500 as Ac-LKKTETQ fragment | Short acetylated heptapeptide from the actin-binding region | ~0.9 kDa class (COAs commonly cite monoisotopic mass near 888.5 Da for Ac-LKKTETQ-OH when salt/solvate is excluded) |
| Ambiguous "TB-500" vial label | Undefined without sequence + MS | Unknown until the COA states it |
Those mass figures are identity anchors, not potency claims. Exact reported masses on a given COA depend on ionization form, adducts, salt, and whether the lab reports monoisotopic or average mass. The researcher's job is to check that the COA's claimed sequence and the reported mass are internally consistent, then that the chromatogram supports a dominant species at that identity.
Why HPLC Purity Alone Cannot Settle Fragment vs Full-Length
Reversed-phase HPLC with UV detection near 214 nm (peptide-bond absorbance) is the workhorse purity method for synthetic peptides. Purity is typically reported as the area percent of the main peak versus all integrated peaks. That answers: "What fraction of UV-active material co-elutes as one peak?" It does not by itself answer: "Is that peak Ac-LKKTETQ or 43-mer Tβ4?"
A short fragment and a full-length chain are different molecules with different retention behavior under a given method — but a COA that only prints "99.5% by HPLC" without a method description, a stated sequence, and orthogonal mass confirmation still leaves identity under-specified. Impurities from solid-phase synthesis (deletion sequences, incomplete acetylation, truncated chains) can also produce related peaks; HPLC area percent does not chemically name them. Mass spectrometry — often LC-MS or LC-HRMS — is what ties a chromatographic peak to a molecular formula / sequence claim.
Practical reading order on a COA:
1. Claimed identity / sequence (exact amino-acid string, N-terminal acetylation, C-terminal acid vs amide).
2. Mass confirmation (measured m/z or deconvoluted mass vs theoretical for that sequence).
3. HPLC purity (area %, wavelength, column class, and whether related substances are listed).
4. Assay / net peptide content if present (peptide vs counter-ion / residual moisture — a separate number from chromatographic purity).
5. Endotoxin / bioburden if claimed (see below — these do not prove pharmaceutical sterility or human safety).
If step 1 is missing, steps 2–5 cannot rescue the document for identity-critical work.
How Commercial COAs Phrase Identity (What to Look For)
Independent lab COAs in this market vary in quality. Stronger reports tend to:
Ac-LKKTETQ-OH (7 residues, N-α acetyl, free C-terminal acid) or identify material as full-length thymosin β4 with a residue count.Weaker reports tend to:
None of this article rates vendors. The distinction is documentary: sequence-stated + mass-matched versus trade-name-only. For how vendors present testing generally, return to the third-party testing guide. For reconstitution solvent and handling logistics after identity is settled, see how to reconstitute TB-500 and the storage and shelf-life guide — those are process articles, not efficacy articles.
Endotoxin and "Cleared" Language Are Not Identity — and Not Human-Safety Proof
Some COAs add bacterial endotoxin results via Limulus Amebocyte Lysate (LAL) methods referenced to USP <85>. A result below a stated EU/mg or EU/mL threshold means the tested aliquot met that laboratory's endotoxin acceptance criterion for a research material. It does not:
Treat endotoxin lines as a separate analytical clause. Useful for lab handling standards some groups require; irrelevant as a substitute for sequence identity; never a clinical clearance.
Research-Use-Only Labeling vs Analytical Identity
"Research use only / not for human consumption" is a commerce and regulatory-positioning label, not an analytical result. It tells you how the seller is positioning the SKU relative to drug-approval frameworks; it does not tell you whether the powder is the fragment or the 43-mer. Conversely, a pristine COA with perfect MS match still does not change the RUO labeling or create an approved indication. Keep those layers separate when reading vendor pages. Broader regulatory posture is covered in our legal status overview and FDA 503A compounding regulations guide — again without use instructions.
Common Failure Modes When Researchers Assume the Name Equals the Sequence
Assuming every "TB-500" vial is Ac-LKKTETQ. Some lots are labeled TB-500 while the COA identity line reads thymosin beta-4 / full-length. If your assay or literature comparison assumes the heptapeptide, that mismatch invalidates the comparison before purity is even discussed.
Assuming every "thymosin β4" vial is pharmaceutical Tβ4. Research-commerce full-length material is still a synthetic research chemical unless it is an approved product under a drug regulatory pathway — which RUO vials are not.
Treating HPLC % as interchangeable across methods. Area percent depends on wavelength, integration rules, and whether impurities absorb similarly at 214 nm. A 99% figure from one method is not automatically comparable to another lab's 99% without method context.
Ignoring net peptide content. A vial labeled "10 mg" may contain a fill weight that includes counter-ions and residual moisture. Chromatographic purity and peptide content answer different questions; conflating them skews concentration calculations for in-vitro work.
Skipping lot matching. A COA for batch A does not analytically support vial from batch B. Chain of custody between the tested sample and the shipped lot is part of identity hygiene, not pedantry.
How This Affects Literature Comparison (Still No Efficacy Claims)
Preclinical and cell-biology papers may use full-length Tβ4, specific fragments, or recombinant constructs. Comparing a commercial vial to a paper without matching the sequence class is a design error, not a minor labeling quibble. This guide deliberately stops at identity hygiene. It does not interpret wound, cardiac, or performance outcomes from any paper, and it does not translate animal or cell findings into human protocols.
Mid-Guide: Sourcing When Identity Documentation Matters
If your work requires lot-level sequence confirmation, prioritize vendors that publish batch-specific COAs with explicit sequence and MS data rather than a generic purity badge. Apollo Peptide Sciences is one supplier that ships TB-500 with published third-party HPLC testing and certificates of analysis — still verify the sequence line and mass on the specific lot COA before treating the material as fragment or full-length. See our peptide buying guide and where to buy TB-500 for the broader sourcing checklist (RUO labeling, shipping, and documentation), not for use advice.
What a Defensible COA Packet Looks Like for Identity Work
A researcher assembling a defensible file for fragment-vs-full-length clarity typically wants:
If any of the first five are missing, the correct scientific response is to withhold identity assumptions — not to infer them from the marketing name "TB-500."
Frequently Asked Questions
Is TB-500 the same thing as thymosin beta-4?
Not reliably in commerce. Primary literature often uses thymosin β4 for the ~43-residue peptide and studies actin-binding fragments such as Ac-LKKTETQ separately. Retail "TB-500" labels may refer to either. Confirm the sequence on the lot COA.
What sequence should appear if the vial is the common research fragment?
COAs that specify the common fragment typically list an N-terminally acetylated heptapeptide written Ac-LKKTETQ-OH (or equivalent residue spelling). If the COA instead identifies full-length thymosin β4, do not treat it as the heptapeptide.
Can HPLC purity tell me whether I have the fragment or full-length peptide?
No. HPLC area percent measures chromatographic purity under a method; mass spectrometry against a stated sequence is what supports molecular identity.
Does a passing endotoxin (USP <85>) result mean the peptide is safe or approved?
No. Endotoxin results speak only to that tested attribute against the lab's criterion. They are not FDA approval, sterility certification for clinical use, or permission for human administration. RUO products remain research materials.
Why do some COAs report both purity and net peptide content?
Because they measure different things. Purity is usually chromatographic area percent of the main species among detected peaks. Net peptide content relates to how much of the weighed powder is peptide versus counter-ions, moisture, or other mass contributors. Both can matter for in-vitro concentration math; neither is a dosing instruction.
Sourcing Checklist (Identity-First)
Before comparing any commercial TB-500 material to a paper or assay that assumes a specific sequence class: read the lot COA sequence line, confirm MS match, then look at purity and content. Apollo Peptide Sciences publishes third-party HPLC/COA documentation for TB-500 lots — use that documentation to verify fragment vs full-length identity rather than trusting the trade name alone. Broader purchasing criteria remain in the peptide buying guide.
---
Related: TB-500 Third-Party Testing and Purity · TB-500 Manufacturing and Synthesis · TB-500 Peptide Buying Guide · Where to Buy TB-500